Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.
Yasukawa
M
M
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan. Electronic address: yasukawa@m.ehime-u.ac.jp.
Ochi
T
T
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan.
Fujiwara
H
H
Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Japan.
D000368:Aged; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology*; D011379:Prognosis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019098:Telomerase / Q000276:immunology*
D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D010446:Peptide Fragments; C509186:TERT protein, human; D019098:Telomerase